Kisspeptin
Also known as: KISS1, KISS1 peptide, Kisspeptin-10, Kisspeptin-54, KP-10, KP-54, Metastin
Source Kisspeptin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Kisspeptin is a neuropeptide that acts as the natural upstream trigger of gonadotropin‑releasing hormone (GnRH) secretion, thereby governing the hypothalamic‑pituitary‑gonadal (HPG) axis. It is being investigated for reproductive‑health applications such as a more physiological trigger of oocyte maturation in IVF, treatment of functional hypothalamic amenorrhea, and modulation of puberty timing.
Mechanism of Action
Kisspeptin binds the G‑protein‑coupled receptor KISS1R (also called GPR54) on hypothalamic GnRH neurons. This activation stimulates pulsatile GnRH release, which in turn drives the pituitary secretion of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), leading to downstream gonadal steroid production. Metabolic cues and neurokinin B modulate kisspeptin neuron activity, linking energy balance and stress to reproductive function.
What the Research Shows
Reviews and mechanistic studies describe kisspeptin as a central regulator of puberty onset, menstrual cyclicity, and reproductive behavior. Genetic mutations in the kisspeptin system underlie some cases of central precocious puberty, highlighting its physiological importance. Early clinical investigations have explored kisspeptin as a trigger for oocyte maturation during IVF, suggesting a more physiological alternative to conventional hCG triggers. Preclinical and translational work also proposes kisspeptin agonists for functional hypothalamic amenorrhea, though human data remain limited. Overall, the evidence is largely from animal models, physiological studies, and small‑scale human trials.
Reported Benefits
Kisspeptin’s ability to induce a natural GnRH surge may provide a safer, more physiologic trigger for oocyte maturation in IVF, potentially reducing ovarian hyperstimulation risk. Its role in restoring GnRH pulsatility offers a theoretical benefit for women with functional hypothalamic amenorrhea, where stress‑related GnRH suppression is a key problem. Additionally, understanding kisspeptin pathways could lead to targeted therapies for disorders of puberty timing.
Limitations of the Evidence
Most data are from preclinical or early‑phase human studies; large, randomized trials are lacking. The therapeutic utility of kisspeptin agonists remains investigational, with no approved indications. Long‑term safety, optimal dosing, and comparative effectiveness versus existing treatments have not been established. Genetic heterogeneity in kisspeptin signaling may limit the applicability of a single therapeutic approach.
Safety Considerations
Safety information is limited to early‑phase investigations. Potential concerns include excessive stimulation of the HPG axis, leading to hormone surges, luteinizing hormone spikes, or ovarian hyperstimulation in susceptible individuals. As an investigational peptide, comprehensive adverse‑event profiles, contraindications, and drug‑interaction data are not yet available.
How It Is Administered
Kisspeptin has been administered experimentally via intranasal, intravenous, and subcutaneous routes. Formulations used in studies range from short‑acting peptide fragments (e.g., KP‑10) to longer‑acting analogues, but commercial products are not currently approved.
Routes of Administration
Goals & Uses
- Tumor metastasis suppression (anti-metastatic)OncologyLow
- Diagnosis of GnRH deficiency (functional test)Diagnostic EndocrinologyModerate
- Induction of ovulationReproductiveModerate
- Suppression of tumor metastasisOncologyLow
- Treatment of hypogonadotropic hypogonadismEndocrinologyModerate
- Improvement of sexual arousal / libidoSexual MedicineLow
- Restoration of reproductive function in hypothalamic amenorrheaReproductive MedicineModerate
- Induction of ovulation / oocyte maturation trigger in IVFReproductive MedicineModerate
Contraindications
- Hormone-sensitive malignanciesOncologyHigh
- Known hypersensitivity to kisspeptin or excipientsAllergy/ImmunologyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe cardiovascular diseaseCardiovascularModerate
- Pituitary insufficiencyEndocrinologyModerate
- Pregnancy (outside of controlled IVF protocols)ObstetricsModerate
Adverse Effects
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Transient decrease in blood pressureCardiovascularUncommon
- Hot flushesVasomotorUncommon
- Ovarian hyperstimulation syndrome (OHSS)ReproductiveRare
Drug Interactions
- GnRH agonists / antagonists (e.g., leuprolide, cetrorelix)Moderate
- Exogenous gonadotropins (FSH, LH, hCG)Moderate
- OpioidsLow
- Opioid analgesicsModerate
Population Constraints
- Pediatric populations (prepubertal)AgeRelative
- Pediatric patientsAgeRelative
- Elderly (>75)AgeRelative
- Patients with active endometriosisGynecologicalRelative
- BreastfeedingReproductiveRelative
- Renal or hepatic impairmentOrgan DysfunctionRelative
Regulatory Status
- European UnionInvestigationalClinical studies ongoing for infertility treatment
- United StatesInvestigationalPhase I/II trials for hypogonadotropic hypogonadism
- United KingdomInvestigationalResearch use only
No jurisdiction has granted full marketing approval for any kisspeptin therapeutic as of 2024. Used as an investigational agent in clinical trials; kisspeptin-54 has been studied in Phase I/II trials in the UK (Imperial College London) and elsewhere for reproductive indications.
Evidence & Sources
- Journal ArticleModerateKoysombat K, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateAguirre RS, Eugster EA2018-01-01T00:00:00.000000Z
- Journal ArticleModerateMeczekalski B, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateSpaziani M, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateNavarro VM2020-01-01T00:00:00.000000Z
- Journal ArticleModerateFuqua JS, Eugster EA2022-01-01T00:00:00.000000Z
Frequently Asked Questions
How does kisspeptin differ from traditional IVF triggers?
Traditional triggers such as hCG act downstream of the natural GnRH surge, whereas kisspeptin directly stimulates GnRH release, mimicking the body’s physiological pathway and potentially reducing the risk of ovarian hyperstimulation.
Can kisspeptin treat early puberty?
Mutations in the kisspeptin system can cause central precocious puberty, but current therapy relies on GnRH analogues. Kisspeptin antagonists or modulators are still under investigation and are not yet available for clinical use.
Is kisspeptin approved for any medical use?
No. Kisspeptin remains an investigational peptide; it has not received regulatory approval for any indication.
What routes are used in research studies?
Research protocols have employed intranasal sprays, intravenous infusions, and subcutaneous injections to deliver kisspeptin peptides, depending on the study design and desired pharmacokinetic profile.
Are there known side effects?
Early studies suggest that excessive GnRH stimulation could lead to hormone spikes or ovarian hyperstimulation, but comprehensive safety data are lacking because large clinical trials have not yet been completed.
What is Kisspeptin?
Kisspeptin is a neuropeptide that acts as the natural upstream trigger of gonadotropin‑releasing hormone (GnRH) secretion, thereby governing the hypothalamic‑pituitary‑gonadal (HPG) axis. It is being investigated for reproductive‑health applications such as a more physiological trigger of oocyte maturation in IVF, treatment of functional hypothalamic amenorrhea, and modulation of puberty timing.
What is Kisspeptin used for?
Kisspeptin is educationally associated with: Tumor metastasis suppression (anti-metastatic), Diagnosis of GnRH deficiency (functional test), Induction of ovulation, Suppression of tumor metastasis, Treatment of hypogonadotropic hypogonadism, Improvement of sexual arousal / libido, Restoration of reproductive function in hypothalamic amenorrhea, Induction of ovulation / oocyte maturation trigger in IVF. Educational only — not medical advice.
How is Kisspeptin administered?
Recorded routes of administration: Intranasal, Intravenous, Subcutaneous.
What are the potential side effects of Kisspeptin?
Reported adverse effects include: Injection site reactions, Headache, Nausea, Transient decrease in blood pressure, Hot flushes, Ovarian hyperstimulation syndrome (OHSS). This list is not exhaustive — consult a qualified clinician.
Who should avoid Kisspeptin?
Recorded contraindications: Hormone-sensitive malignancies, Known hypersensitivity to kisspeptin or excipients, Pregnancy, Severe cardiovascular disease, Pituitary insufficiency, Pregnancy (outside of controlled IVF protocols). Consult a qualified clinician before use.